Korean biopharmaceutical companies are turning to rights offering from investors and institutions to raise insufficient funds.A rights offer can help companies raise secondary capital by issuing rights to the company's existing shareholders to buy additional shares in proportion to their existing sh
Boryung said it received product approval from the Ministry of Food and Drug Safety for Zepzelca (Ingredient: lurbinectedin), a small cell lung cancer (SCLC) drug licensed-in from PharmaMar, a Spanish-based pharmaceutical company, in 2017.Under the approval, hospitals can use the drug in treating pa
HK inno.N said it would develop an ointment with a JAK inhibitor mechanism to treat atopic dermatitis (AD).At an investor relations meeting on Wednesday, the Kosdaq-listed firm unveiled the status of major pipelines. In particular, the company introduced a new drug candidate IN-A002 in the JAK-1 inh
The Korea Exchange (KRX) will review and decide on whether to delist Kolon Tissugene, SillaJen, and Qurient in October, as the three companies have submitted all the details of the implementation of improvement plans. The three companies had received a grace period from the KRX to improve their busi
PARP inhibitors, which had emerged as the most common targeted therapy for unresectable ovarian cancer, could increase death risk in patients who experienced several chemotherapies, a recent study showed, forcing developers to withdraw their indications.AstraZeneca reportedly distributed an official
MSD Korea said on Friday that Keytruda (ingredient: pembrolizumab) obtained domestic approval as a combination therapy with chemotherapy, with or without bevacizumab, as the primary treatment for patients with persistent, recurrent or metastatic cervical cancer.Consequently, Keytruda has now been ap
HanAll Biopharma and Yuyu Pharmaceutical are accelerating efforts to develop dry eye treatments, witnessing a global increase in the prevalence of the disease, also known as xerophthalmia.According to a study published in the Ophthalmic and Physiological Optics, a research journal of optometrists, t
It is becoming increasingly important for individual researchers or research institutes to conduct research after proposing research topics. This is because the results of the study are reflected in clinical treatment guidelines or incentivize the development of new drugs and medical devices. In the
Spectrum Pharmaceuticals, Hanmi Pharmaceutical’s U.S. partner, said the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted nine to four against poziotinib, a lung cancer drug candidate, saying benefits of the drug did not outweigh risks.Poziotinib aims to treat
Dupixent (dupilumab), the first approved biological drug for treating atopic dermatitis, has not just improved symptoms in oral corticosteroid-dependent asthma patients but demonstrated the effect of reducing steroid use.Sanofi said so, releasing its three-year, long-term data on severe asthma patie
The Korean market for ginkgo leaf extracts that improve blood circulation disorders and cognitive impairment is growing rapidly.According to UBIST, a drug market research firm, domestic sales of Ginkgo biloba extract preparations grew from 40.4 billion won ($28.6 million) in 2017 to 56.6 billion won
Janssen’s Imbruvica (ibrutinib) and BeiGene’s Brukinsa (zanubrutinib), the two BTK (bruton tyrosine kinase) inhibitors with the same mechanism, received two different review results from the Health Insurance Review and Assessment Service’s (HIRA) cancer drug reimbursement review committee.The review
Celltrion is drawing the industry’s attention by setting about to develop a new drug based on a bispecific antibody to treat HER2-positive breast cancer.Celltrion said Wednesday that it signed a contract with Abpro Corp., a U.S. bio company, to co-develop ABP102, a bispecific treatment candidate tar
Moderna's top medical officer said the U.S.-based biopharmaceutical company will continue to use its worldwide manufacturing facilities, despite President Joe Biden’s new $2 billion initiative to support for biomanufacturing in the U.S.Earlier this month, Biden signed an executive order to launch a
Shaperon said it would strive to be a leader in autoimmune disease treatment by going public on the Kosdaq market in October.Shaperon started as a Seoul National University venture in 2008 based on the world's first inflammation initiation theory, DAMP (Damage Associated Molecular Patterns), discove
HLB’s U.S. affiliate, Verismo Therapeutics and GC Cell’s U.S. affiliate, Artiva Biotherapeutics announced this week that they obtained phase 1 IND approval from the FDA for their respective next-generation chimeric antigen receptor (CAR-T) treatments.Accordingly, Verismo will evaluate the safety, re
The U.S. Food and Drug Administration (FDA) on Tuesday raised concerns over the safety and efficacy of poziotinib, a non-small cell lung cancer (NSCLC) licensed out by Hanmi Pharmaceutical to Spectrum Pharmaceuticals. Poziotinib aims to treat NSCLC with locally advanced and metastatic HER2 Exon 20 i
Celltrion said on Tuesday that it won a patent invalidation lawsuit against Roche (Genentech) in Taiwan for the Rheumatoid Arthritis (RA) indication of Truxima, a biosimilar of the original drug Rituxan (ingredient name: rituximab).Celltrion had previously invalidated the related patent in Korea in
SillaJen said it inked a deal with Basilea Pharmaceutica, a Switzerland-based biopharmaceutical company, to license in the latter's BAL0891, an anticancer drug candidate.Under the agreement, Basilea will receive an upfront payment of $14 million and can receive up to $335 million for milestones acco
Drugmakers are gearing up to race in the development of a denosumab biosimilar to treat various bone diseases. Sandoz, a subsidiary of Novartis handling off-patent medicines, said on Monday that it confirmed positive results from a study of a proposed biosimilar denosumab (original brands: Prolia, X